PFGIA
KPTI icon

Patriot Financial Group Insurance Agency’s Karyopharm Therapeutics KPTI Stock Holding History

Patriot Financial Group Insurance Agency’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,583
Closed -$249K – 2157
2021
Q4 		$249K Buy
2,583
+2,316
+867% +$231K 0.04% 397
2021
Q3 		$23K Buy
267
+40
+18% +$4.15K ﹤0.01% 1159
2021
Q2 		$35K Buy
227
+80
+54% +$11.6K 0.01% 960
2021
Q1 		$23K Buy
+147
New +$31K 0.01% 1036

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ITP
Iron Triangle Partners Cos Cob, Connecticut $875M AUM 49.85% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Patriot Financial Group Insurance Agency's KPTI Position: Q1 2022 in Review

Patriot Financial Group Insurance Agency sold out of Karyopharm Therapeutics (KPTI) in Q1 2022, closing a stake of 2,583 shares — an estimated $249K sold.

Patriot Financial Group Insurance Agency first reported a position in KPTI in Q1 2021 and held it in 4 quarters. The position peaked at $249K in Q4 2021. 139 funds tracked by Wall St. Rank hold KPTI as of Q1 2022.

  • Patriot Financial Group Insurance Agency reported no remaining Karyopharm Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Patriot Financial Group Insurance Agency sold 2,583 Karyopharm Therapeutics shares in Q1 2022, an estimated $249K.
  • Patriot Financial Group Insurance Agency first reported a position in Karyopharm Therapeutics in Q1 2021 and held it in 4 quarters.
  • Patriot Financial Group Insurance Agency's Karyopharm Therapeutics position peaked at $249K in Q4 2021.
  • 139 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2022.

Based on Patriot Financial Group Insurance Agency's 13F filing for Q1 2022, filed 11 May 2022.